Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
April 26, 2026LifeOpen Access

Network Pharmacology and Molecular Docking-Based Investigation of Empagliflozin’s Therapeutic Potential in Chronic Kidney Disease

View Full Paper
Ask AI
Bookmark
Share

Authors

ATAman TedasenMCMoragot ChatatikunRNRatana Netphakdee

Discussion

Loading...

Member takes

Overview

Network pharmacology reveals empagliflozin's multi-target mechanisms in CKD, suggesting its therapeutic significance.

Key Points

  • The study aims to explore the therapeutic mechanisms of empagliflozin in chronic kidney disease using network pharmacology and molecular docking.
  • Employing an integrated network pharmacology and molecular docking approach
  • Evaluating physicochemical properties and molecular interactions
  • Identifying shared molecular targets and performing pathway enrichment analysis
  • Identified 221 molecular targets shared between empagliflozin and CKD-associated genes.
  • Molecular docking simulations showed strong binding affinities with HSP90AB1 (−10.85 kcal/mol), MAPK3 (−9.46 kcal/mol) and EGFR (−9.38 kcal/mol).
  • Pathway analyses highlighted critical roles of phosphorylation and signaling pathways in CKD progression.

Cite This Study

Tedasen et al. (2026) studied this question.

synapsesocial.com/papers/69edad274a46254e215b4cfehttps://doi.org/10.3390/life16050719
View Full Paper
Ask AI
Bookmark
Share